{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-069169","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2025-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.453955+00:00","generated_at":"2026-05-18T05:17:49.119110+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ArriVent projects topline phase 3 FURVENT data for firmonertinib in early 2026","bullets":["Topline firmonertinib monotherapy data from pivotal Phase 3 FURVENT study in 1L NSCLC EGFR exon20ins projected early 2026.","Primary endpoint is progression-free survival by blinded independent central review per RECIST 1.1.","Enrollment in the global FURVENT study completed in Q1 2025.","Firmonertinib previously received FDA Breakthrough Therapy Designation for this patient population."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-069169","json":"https://secwatch.observer/filing/0001104659-25-069169.json","markdown":"https://secwatch.observer/filing/0001104659-25-069169.md","text":"https://secwatch.observer/filing/0001104659-25-069169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465925069169/0001104659-25-069169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465925069169/tm2521271d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:17:49.119110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}